| Almirall says it is delighted with Recordati agreement | Posted on 06/04/2009 in Pharmaceutical Company Product News Almirall is "delighted" to have reached an agreement with Recordati to co-market silodosin.
The Spain-based pharmaceutical company will work with the latter to advertise and sell the capsule that is designed to be taken once a day for benign prostate hyperplasia (BPH).
It reduces prostate enlargement symptoms by blocking alpha-1 adrenergic receptors in this organ, as well as in the bladder and urethra.
The arrangement will help strengthen its core business and Jorge Gallardo, chairman and chief executive officer of the firm, explained it would aid the high percentage of men who are affected by the condition in Spain.
"We ? are convinced that by incorporating silodosin into our product portfolio we will enhance our urology area while offering an efficient solution to improve quality of life for BPH sufferers," he remarked.
Last month, Almirall released figures showing total revenues for 2008 were 136.1 million euros (123.5 million pounds) ? an increase of 3.8 per cent from the year before. Net sales also rose by 13.9 per cent to 902.8 million euros.Other news stories from 06/04/2009
Read more in the Zenopa News Archive
How this news is generated
|  |
|
